Pfizer Q4 Earnings

PFE Earnings: Pfizer Stock Jumps on Q4 Beats
Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See why I rate PFE stock as a Hold.
Pfizer beats Q4, FY '24 earnings estimates, stock flat in early trading
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 billion in revenue for the full year,
Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance
We remain confident in our ability to return to pre-pandemic operating margins in the coming years,” said Pfizer CFO David Denton.
Pfizer: Q4 Earnings Snapshot
The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of 48 cents per share. The drugmaker posted revenue of $17.76 billion in the period, also exceeding Street forecasts.
Pfizer Beats Q4 Revenue, EPS Estimates
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.
Pfizer 4Q Revenue Beat Leads to Swing to Profit
Revenue rose to $17.76 billion from $14.57 billion. Analysts polled by FactSet had expected $17.35 billion. Chief Financial Officer David Denton said Pfizer remains on track to deliver $1.5 billion of net cost savings by the end of 2027,
Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President,
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
If You Invested $10,000 In Pfizer Stock 10 Years Ago, How Much Would You Have Now?
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...
Should You Pick PFE Stock At $25?
Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...
Can This Beaten-Down Stock Bounce Back in 2025?
However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in between $61 billion and $64 billion -- the same projection it made for the ...
Truist Financial Remains a Buy on Pfizer (PFE)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report). The company’s ...
Yahoo Finance5d
Pfizer, Inc. (PFE) stock forecast and price target
Find the latest Pfizer, Inc. PFE analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Pfizer's Options: A Look at What the Big Money is Thinking
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...